During the ASCO conference, Dr Floris Verheij, a research fellow at the Memorial Sloan Kettering Cancer Institute in New York, USA, presented the long-term results of the OPRA trial. The OPRA trial focused on patients with locally advanced rectal cancer and aimed to evaluate the effectiveness of total neoadjuvant therapy in achieving organ preservation.
The preliminary results of the OPRA trial had already demonstrated promising outcomes, showing that a significant number of patients with locally advanced rectal cancer could achieve organ preservation through the use of total neoadjuvant therapy.
In Dr Verheij’s presentation at ASCO, the long-term organ preservation rate and oncologic outcomes of the OPRA trial were shared. These results provide valuable insights into the durability of organ preservation achieved through total neoadjuvant therapy and the impact on the overall oncologic outcomes for patients with locally advanced rectal cancer.
With the educational support of:
